首页 › 慢性淋巴细胞白血病 › 路易斯安那州 › Baton Rouge
Baton Rouge LA 慢性淋巴细胞白血病临床试验
5项针对 慢性淋巴细胞白血病的研究正在 Baton Rouge及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Mary Bird Perkins Cancer Center, Baton Rouge
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- Our Lady of The Lake, Baton Rouge
- 以及另外 2 项
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
招募中3 期
- Our Lady of the Lake Hospital, Baton Rouge
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
招募中3 期
- Mary Bird Perkins Cancer Center, Baton Rouge
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- Our Lady of the Lake Hospital, Baton Rouge
- Mary Bird Perkins Cancer Center, Baton Rouge
其他城市的 慢性淋巴细胞白血病试验
- Boston, MA31 项研究
- Columbus, OH28 项研究
- Durham, NC27 项研究
- Washington, DC22 项研究
- Seattle, WA20 项研究
- Rochester, MN18 项研究
- New York City, NY18 项研究
- Houston, TX17 项研究
- Baldwin Park, CA16 项研究
- Milwaukee, WI15 项研究
- Chicago, IL14 项研究
- Cincinnati, OH14 项研究
Baton Rouge的其他研究
- 肥胖症15 项研究
- 超重10 项研究
- 非小细胞肺癌10 项研究
- 转移性癌症9 项研究
- 急性髓系白血病8 项研究
- 肺癌8 项研究
- 结直肠癌8 项研究
- 乳腺癌7 项研究
- 膀胱癌6 项研究
- 前列腺癌5 项研究
- 慢性阻塞性肺病5 项研究
- 心力衰竭5 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。